Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert James Mayer, M.D.

Co-Author

This page shows the publications co-authored by Robert Mayer and Monica Bertagnolli.
Connection Strength

1.337
  1. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87.
    View in: PubMed
    Score: 0.137
  2. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol. 2011 Aug 10; 29(23):3153-62.
    View in: PubMed
    Score: 0.118
  3. Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581. J Clin Oncol. 2009 May 20; 27(15_suppl):4012.
    View in: PubMed
    Score: 0.102
  4. KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. J Clin Oncol. 2009 May 20; 27(15_suppl):4037.
    View in: PubMed
    Score: 0.102
  5. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res. 2009 Mar 15; 15(6):2116-22.
    View in: PubMed
    Score: 0.101
  6. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009 Apr 10; 27(11):1814-21.
    View in: PubMed
    Score: 0.101
  7. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10003.
    View in: PubMed
    Score: 0.083
  8. Cancer and leukemia group B gastrointestinal cancer committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3589s-95s.
    View in: PubMed
    Score: 0.083
  9. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg. 2004 Oct; 240(4):624-8; discussion 628-30.
    View in: PubMed
    Score: 0.074
  10. Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Ann Oncol. 2017 Jun 01; 28(6):1359-1367.
    View in: PubMed
    Score: 0.045
  11. Reply to L. Casadaban et al. J Clin Oncol. 2017 04 20; 35(12):1373-1374.
    View in: PubMed
    Score: 0.043
  12. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). J Clin Oncol. 2016 09 01; 34(25):3047-53.
    View in: PubMed
    Score: 0.042
  13. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013 Dec 04; 105(23):1789-98.
    View in: PubMed
    Score: 0.035
  14. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012 Feb 01; 18(3):890-900.
    View in: PubMed
    Score: 0.030
  15. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011 Oct 19; 103(20):1540-51.
    View in: PubMed
    Score: 0.030
  16. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol. 2011 Aug 10; 29(23):3146-52.
    View in: PubMed
    Score: 0.030
  17. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009 Dec 01; 15(23):7322-9.
    View in: PubMed
    Score: 0.026
  18. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA. 2008 Jun 04; 299(21):2515-23.
    View in: PubMed
    Score: 0.024
  19. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007 Jan; 132(1):127-38.
    View in: PubMed
    Score: 0.021
  20. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol. 2006 Feb 20; 24(6):878-83.
    View in: PubMed
    Score: 0.020
  21. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer. 2004 Dec 10; 112(5):754-9.
    View in: PubMed
    Score: 0.019
  22. APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther. 2004 Oct; 3(10):960-4.
    View in: PubMed
    Score: 0.019
  23. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004 May 01; 64(9):3014-21.
    View in: PubMed
    Score: 0.018
  24. Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther. 2004 Jan; 3(1):73-8.
    View in: PubMed
    Score: 0.018
  25. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res. 2003 Apr 01; 63(7):1608-14.
    View in: PubMed
    Score: 0.017
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.